Summary
The cause of neuronal cell death in Parkinson’s disease is unknown but there is accumulating evidence suggesting that oxidative stress may be involved in this process. Current evidence shows that in the substantia nigra there is altered iron metabolism, decreased levels of reduced glutathione and an impairment of mitochondrial complex I activity. However, these changes seem to be unique to the substantia nigra and have not been found in other areas of the brain known to be altered in Parkinson’s disease, such as substantia innominata. In addition they do not appear to be related to the presence of Lewy bodies, as other areas of the brain containing Lewy bodies do not show evidence of either oxidative stress or mitochondrial dysfunction. Oxidative stress has now been demonstrated in Alzheimer’s disease and its presence appears to be correlated with regions of marked pathological changes.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Dexter DT, Wells FR, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD (1987) Increased nigral iron content in post-mortem parkinsonian brain. Lancet ii: 219–220.
Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52: 381–389.
Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in the brain in Parkinson’s disease. J Neurochem 52: 1830–1836.
Dexter DT, Carayon A, Vidaillhet M, Ruberg M, Agid F, Agid Y, Lees AJ, Wells FR, Jenner P, Marsden CD (1990) Decreased ferritin levels in brain in Parkinson’s disease. J Neurochem 55: 16–20.
Dexter DT, Sian J, Jenner P, Marsden CD (1993) Implications of alterations in trace element levels in brain in Parkinson’s disease and other neurological disorders affecting the basal ganglia. Adv Neurol 60: 273–281.
Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, Cooper JM, Wells FR, Daniel S, Lees AJ, Schapira AHV, Jenner P, Marsden CD (1994) Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy Body disease. Ann Neurol 35: 38–44.
Jenner P (1994) Oxidative damage in neurodegenerative disease. Lancet 344: 796–798.
Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AHV (1994) Complex I, iron and ferritin in Parkinson’s disease substantia nigra. Ann Neurol 36: 876–881.
Mastrogiacomo F, Bergeron C, Kish SJ (1993) Brain α-ketoglutarate dehydrogenase complex activity in Alzheimer’s disease. J Neurochem 61: 2007–2014.
Mecocci P, MacGarvey U, Flint-Beal M (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36: 747–751.
Mizuno Y, Matsuda S, Yoshina H, Mori H, Hattori N (1994) An immunohistochemical study of α-ketoglutarate dehydrogenase complex in Parkinson’s disease. Ann Neurol 35: 204–210.
Palmer AM, Burns MA (1994) Selective increase in lipid peroxidation in the inferior temporal cortex in Alzheimer’s disease. Brain Res 645: 338–342.
Parker WD, Parks JK (1995) Cytochrome c oxidase in Alzheimer’s disease brain: purification and characterization. Neurol 45: 482–486.
Perry T, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency. Neurosci Lett 33: 305–310.
Perry E, McKeith I, Perry R (1996) Dementia with Lewy bodies: clinical, pathological and treatment issues. Cambridge University Press.
Reiderer P, Sofie E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MB (1989) Transition metals, ferritin, glutathione and ascorbic acid in Parkinson’s disease. J Neurochem 52: 381–389.
Sanchezramos JR, Overvik E, Ames BN (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson’s disease brain. Neurodegeneration 3: 197–204.
Schapira AHV, Cooper JM, Dexter DT, Clark JB, Jenner P, Marsden CD (1990a) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54: 823–827.
Schapira AHV, Mann VM, Cooper JM, Dexter DT, Daniel SE, Jenner P, Clark JB, Marsden CD (1990b) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson’s disease. J Neurochem 55: 2142–2145.
Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting the basal ganglia. Ann Neurol 36: 348–355.
Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD (1994) Glutathione-related enzymes in brain in Parkinson’s disease. Ann Neurol 36: 356–361.
Sofic E, Reiderer P, Heinsen, Beckmann H, Reynolds GP, Hebenstreit G, Youdim MB (1988) Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm 74: 199–205.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag/Wien
About this paper
Cite this paper
Owen, A.D., Schapira, A.H.V., Jenner, P., Marsden, C.D. (1997). Indices of oxidative stress in Parkinson’s disease, Alzheimer’s disease and dementia with Lewy bodies. In: Daniel, S.E., Cruz-Sánchez, F.F., Lees, A.J. (eds) Dementia in Parkinsonism. Journal of Neural Transmission. Supplementa, vol 51. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6846-2_14
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6846-2_14
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-82959-2
Online ISBN: 978-3-7091-6846-2
eBook Packages: Springer Book Archive